This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Name: GDC-6036
Description: Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
Measure: Percentage of Participants With Adverse Events (AEs) Time: From baseline up until 28 days after the final doseSequential Assignment
There is one SNP
A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation. --- G12C ---
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. --- G12C ---
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. --- G12C --- --- G12C ---
Inclusion Criteria: - Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation. --- G12C ---